Acne Scars, Acne Scars - Atrophic
Conditions
Brief summary
This study aims to evaluate the efficacy and safety of intradermal injection of autologous stromal vascular fraction (SVF) in the treatment of atrophic acne scars. SVF is a heterogeneous cell population derived from adipose tissue, containing various regenerative and immunomodulatory cells, including mesenchymal stem cells, endothelial progenitor cells, and pericytes. In this prospective, randomized, split-face clinical trial, participants with atrophic acne scars will receive SVF injections on one side of the face and normal saline (NS) injections on the contralateral side as a control. Clinical efficacy will be assessed through blinded scar counts, digital imaging, and histological evaluations including epidermal and dermal regenerative markers. The study is designed to investigate whether SVF provides superior clinical improvement compared to placebo.
Interventions
BIOLOGICALstromal vascular fraction (SVF)
Autologous stromal vascular fraction (SVF) isolated from adipose tissue was injected intradermally into one side of the face to evaluate its efficacy in treating atrophic acne scars. SVF was freshly prepared on the same day of injection using enzymatic digestion and centrifugation.
OTHERNormal Saline (NS)
Normal saline (NS) was injected intradermally into the contralateral side of the face and served as a placebo comparator to SVF in this split-face study on atrophic acne scars.
Sponsors
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Age between 19 and 45 years * Presence of bilateral atrophic acne scars (boxcar, rolling, or icepick types) on the face * Willingness to undergo fat harvesting procedure * Ability to comply with study visits and follow-up * Written informed consent obtained
Exclusion criteria
* Active acne lesions on the treatment area * History of keloid or hypertrophic scarring * Prior treatment for acne scars (e.g., laser, filler, microneedling) within the past 6 months * History of systemic immunosuppressive therapy within the past 3 months * Pregnant or breastfeeding women * Any systemic disease that may interfere with wound healing or safety assessment (e.g., uncontrolled diabetes, collagen vascular disease)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in total number of atrophic acne scars from baseline to Week 5 | Baseline and 5 weeks after treatment |
| Change in total number of atrophic acne scars from baseline to Week 10 | Baseline and 10 weeks after treatment |
Contacts
Primary ContactDae Hun Suh
Outcome results
None listed